Your browser doesn't support javascript.
loading
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek, Srdan; Mesa, Ruben A; Gotlib, Jason; Gupta, Vikas; DiPersio, John F; Catalano, John V; Deininger, Michael W N; Miller, Carole B; Silver, Richard T; Talpaz, Moshe; Winton, Elliott F; Harvey, Jimmie H; Arcasoy, Murat O; Hexner, Elizabeth O; Lyons, Roger M; Paquette, Ronald; Raza, Azra; Jones, Mark; Kornacki, Deanna; Sun, Kang; Kantarjian, Hagop.
Afiliación
  • Verstovsek S; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 418, Houston, TX, 77030, USA. sverstov@mdanderson.org.
  • Mesa RA; Mayo Clinic Cancer Center, 13400 E. Shea Blvd, Scottsdale, AZ, 85259, USA.
  • Gotlib J; Stanford Cancer Institute, 875 Blake Wilbur Drive, Room 2324, Stanford, CA, 94305, USA.
  • Gupta V; Princess Margaret Cancer Center, University of Toronto, 610 University Avenue, Suite 5-217, Toronto, M5G 2M9, Canada.
  • DiPersio JF; Washington University School of Medicine, 660S Euclid Ave., St. Louis, MO, 63110, USA.
  • Catalano JV; Frankston Hospital and Department of Clinical Haematology, Monash University, 2 Hastings Rd, Frankston, VIC, 3199, Australia.
  • Deininger MW; University of Utah Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.
  • Miller CB; Division of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
  • Silver RT; Saint Agnes Cancer Institute, 900S Caton Ave., Baltimore, MD, 21229, USA.
  • Talpaz M; Weill Cornell Medical Center, 525 East 68th St., Payson Pavilion 3, New York, NY, 10021, USA.
  • Winton EF; University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI, 48109, USA.
  • Harvey JH; Emory University School of Medicine, 1365 C Clifton Rd. Suite 1152, Atlanta, GA, 30322, USA.
  • Arcasoy MO; Birmingham Hematology and Oncology, 1024 First St North, Birmingham, AL, 35204, USA.
  • Hexner EO; Duke University Health System, DUMC 3912, Durham, NC, 27710, USA.
  • Lyons RM; Abramson Cancer Center at the University of Pennsylvania, 3400 Civic Center Blvd., PCAM 2 West Pavilion, Philadelphia, PA, 19104, USA.
  • Paquette R; Texas Oncology and US Oncology Research, 4411 Medical Dr., San Antonio, TX, 78229, USA.
  • Raza A; Cedars-Sinai, 10833 Le Conte Ave., 42-121 CHS, Los Angeles, CA, 90024, USA.
  • Jones M; Columbia University Medical Center, Milstein Hospital Building, 6N-435, 177 Fort Washington Ave., New York, NY, 10032, USA.
  • Kornacki D; Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA.
  • Sun K; Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA.
  • Kantarjian H; Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA.
J Hematol Oncol ; 10(1): 55, 2017 02 22.
Article en En | MEDLINE | ID: mdl-28228106
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Mielofibrosis Primaria Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Mielofibrosis Primaria Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos